Invention Grant
- Patent Title: Set of genes for molecular classifying of medulloblastoma and use thereof
-
Application No.: US17271215Application Date: 2019-09-06
-
Publication No.: US11312999B2Publication Date: 2022-04-26
- Inventor: Qinghua Xu , Chengshu Chen , Yifeng Sun , Jinying Chen , Qifeng Wang , Kaibin Song
- Applicant: HANGZHOU CANHELP GENOMICS TECHNOLOGY CO. LTD.
- Applicant Address: CN Hangzhou
- Assignee: HANGZHOU CANHELP GENOMICS TECHNOLOGY CO. LTD.
- Current Assignee: HANGZHOU CANHELP GENOMICS TECHNOLOGY CO. LTD.
- Current Assignee Address: CN Hangzhou
- Agency: Bayramoglu Law Offices LLC
- Priority: CN201811043820.3 20180907
- International Application: PCT/CN2019/104613 WO 20190906
- International Announcement: WO2020/048518 WO 20200312
- Main IPC: C12P19/34
- IPC: C12P19/34 ; C12Q1/6886 ; C12Q1/6806 ; C12Q1/6837

Abstract:
A set of genes for the molecular classifying of medulloblastoma is disclosed, including the following 24 genes: EPHA7 gene, OTX2 gene, ROBO1 gene, TTR gene, LGR5 gene, IGF2BP3 gene, TBR1 gene, ZFPM2 gene, TRDC gene, TRAC gene, PEX5L gene, NKD1 gene, RALYL gene, GABRA5 gene, GAD1 gene, TNC gene, KCNA1 gene, EOMES gene, MAB21L2 gene, WIF1 gene, DKK2 gene, PDLIM3 gene, IMPG2 gene, and KHDRBS2 gene. In addition, the present invention also discloses the use of the genome in the preparation of a kit and a gene chip for the molecular classifying of medulloblastoma. After validation, the present invention can accurately differentiate medulloblastoma WNT subgroup, SHE subgroup, Group3 subgroup, and Group4 subgroup, and has important clinical significance for the precise treatment of patients due to the objective results, high accuracy, and short experimental period.
Public/Granted literature
- US20210254179A1 SET OF GENES FOR MOLECULAR CLASSIFYING OF MEDULLOBLASTOMA AND USE THEREOF Public/Granted day:2021-08-19
Information query